Signal Transduction and Targeted Therapy-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2265912, encodeId=412c226591236, content=偏重的研究方向：免疫 经验分享：自投综述，无约稿。经历供参考。 ·2025.5.20(周二，上午)发邮件给编辑询问是否接受综述投稿，并提供主要内容。 ·2025.5.20（周二，下午）非常感谢您提交前的询问。提议的主题很有趣也很重要。【然而，我们在类似或更大的主题上也有评审，要么在同行评审中，要么在修订中。因此，这个主题不在我们今年的优先主题列表中。】我们对这个负面的回应感到抱歉。非常感谢您的理解。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffeb5424961, createdName=ms2000001547783895, createdTime=Tue May 20 18:58:16 CST 2025, time=2025-05-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2248369, encodeId=1364224836999, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：还在under Consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0e95702647, createdName=ms1000000283885765, createdTime=Thu Jan 16 19:20:06 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2248373, encodeId=2eb322483e37a, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：正在投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0e95702647, createdName=ms1000000283885765, createdTime=Thu Jan 16 19:25:47 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230656, encodeId=2e16223065675, content=第一轮大修后迎来小修，小修返回去后editor assigned已经半个月了，请问大家这是什么情况啊。。也不敢发邮件询问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b48346217, createdName=ms3000000263143818, createdTime=Sun Oct 13 21:22:13 CST 2024, time=2024-10-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2160074, encodeId=0ff121600e444, content=Manuscript Under Consideration一般多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=380, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14938341371, createdName=ms6000001571479804, createdTime=Wed Sep 27 18:15:41 CST 2023, time=2023-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=972892, encodeId=24729e289276, content=投稿11天被拒，着急的人慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210611/d83e222ca83744579abc7ae60aec94b4/d3ddb54b1ac74080bbe927391f78ad1a.jpg, createdBy=36415493698, createdName=志志呀, createdTime=Fri Jun 11 16:31:06 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125871, encodeId=ff1d21258e126, content=偏重的研究方向：肝脏;肠道 经验分享：想问问大家审稿2个月了，还没有任何的回复，不会给我拒绝了吧，这么久了。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Fri Apr 14 10:58:54 CST 2023, time=2023-04-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2232131, encodeId=1103223213193, content=请问一下，直接投STTT的研究性Letter难度咋样？比如比起STTT或者其它十分左右杂志的Article，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=sucao, createdTime=Mon Oct 21 14:11:49 CST 2024, time=2024-10-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1059450, encodeId=093c10594501c, content=大家有类似的经历吗？预接收以后过了25天还未正式接收（9月13日预接收，15日返回修改版，之后状态一直是editor assigned）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=402, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhFQWJcqrIHncZhicFVfK89RBPRlh6RHemwCJGbAu6sf2BgPbVkfYbE2KOnIAvbXIk2KFhqbLoIeQ/132, createdBy=45865313245, createdName=cewei, createdTime=Mon Oct 11 13:37:29 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150081, encodeId=b992215008172, content=正在投稿中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d4b5542563, createdName=ms2000002060596419, createdTime=Thu Jul 27 10:52:45 CST 2023, time=2023-07-27, status=1, ipAttribution=广东省)]

2025-05-20 ms2000001547783895 来自浙江省

偏重的研究方向：免疫
经验分享：自投综述，无约稿。经历供参考。
·2025.5.20(周二，上午)发邮件给编辑询问是否接受综述投稿，并提供主要内容。
·2025.5.20（周二，下午）非常感谢您提交前的询问。提议的主题很有趣也很重要。【然而，我们在类似或更大的主题上也有评审，要么在同行评审中，要么在修订中。因此，这个主题不在我们今年的优先主题列表中。】我们对这个负面的回应感到抱歉。非常感谢您的理解。

7 0

[GetPortalCommentsPageByObjectIdResponse(id=2265912, encodeId=412c226591236, content=偏重的研究方向：免疫 经验分享：自投综述，无约稿。经历供参考。 ·2025.5.20(周二，上午)发邮件给编辑询问是否接受综述投稿，并提供主要内容。 ·2025.5.20（周二，下午）非常感谢您提交前的询问。提议的主题很有趣也很重要。【然而，我们在类似或更大的主题上也有评审，要么在同行评审中，要么在修订中。因此，这个主题不在我们今年的优先主题列表中。】我们对这个负面的回应感到抱歉。非常感谢您的理解。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffeb5424961, createdName=ms2000001547783895, createdTime=Tue May 20 18:58:16 CST 2025, time=2025-05-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2248369, encodeId=1364224836999, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：还在under Consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0e95702647, createdName=ms1000000283885765, createdTime=Thu Jan 16 19:20:06 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2248373, encodeId=2eb322483e37a, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：正在投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0e95702647, createdName=ms1000000283885765, createdTime=Thu Jan 16 19:25:47 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230656, encodeId=2e16223065675, content=第一轮大修后迎来小修，小修返回去后editor assigned已经半个月了，请问大家这是什么情况啊。。也不敢发邮件询问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b48346217, createdName=ms3000000263143818, createdTime=Sun Oct 13 21:22:13 CST 2024, time=2024-10-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2160074, encodeId=0ff121600e444, content=Manuscript Under Consideration一般多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=380, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14938341371, createdName=ms6000001571479804, createdTime=Wed Sep 27 18:15:41 CST 2023, time=2023-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=972892, encodeId=24729e289276, content=投稿11天被拒，着急的人慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210611/d83e222ca83744579abc7ae60aec94b4/d3ddb54b1ac74080bbe927391f78ad1a.jpg, createdBy=36415493698, createdName=志志呀, createdTime=Fri Jun 11 16:31:06 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125871, encodeId=ff1d21258e126, content=偏重的研究方向：肝脏;肠道 经验分享：想问问大家审稿2个月了，还没有任何的回复，不会给我拒绝了吧，这么久了。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Fri Apr 14 10:58:54 CST 2023, time=2023-04-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2232131, encodeId=1103223213193, content=请问一下，直接投STTT的研究性Letter难度咋样？比如比起STTT或者其它十分左右杂志的Article，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=sucao, createdTime=Mon Oct 21 14:11:49 CST 2024, time=2024-10-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1059450, encodeId=093c10594501c, content=大家有类似的经历吗？预接收以后过了25天还未正式接收（9月13日预接收，15日返回修改版，之后状态一直是editor assigned）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=402, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhFQWJcqrIHncZhicFVfK89RBPRlh6RHemwCJGbAu6sf2BgPbVkfYbE2KOnIAvbXIk2KFhqbLoIeQ/132, createdBy=45865313245, createdName=cewei, createdTime=Mon Oct 11 13:37:29 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150081, encodeId=b992215008172, content=正在投稿中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d4b5542563, createdName=ms2000002060596419, createdTime=Thu Jul 27 10:52:45 CST 2023, time=2023-07-27, status=1, ipAttribution=广东省)]

2025-01-16 ms1000000283885765 来自北京

审稿速度:1.0 | 投稿命中率:5.0
偏重的研究方向：免疫
经验分享：还在under Consideration

0 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2265912, encodeId=412c226591236, content=偏重的研究方向：免疫 经验分享：自投综述，无约稿。经历供参考。 ·2025.5.20(周二，上午)发邮件给编辑询问是否接受综述投稿，并提供主要内容。 ·2025.5.20（周二，下午）非常感谢您提交前的询问。提议的主题很有趣也很重要。【然而，我们在类似或更大的主题上也有评审，要么在同行评审中，要么在修订中。因此，这个主题不在我们今年的优先主题列表中。】我们对这个负面的回应感到抱歉。非常感谢您的理解。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffeb5424961, createdName=ms2000001547783895, createdTime=Tue May 20 18:58:16 CST 2025, time=2025-05-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2248369, encodeId=1364224836999, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：还在under Consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0e95702647, createdName=ms1000000283885765, createdTime=Thu Jan 16 19:20:06 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2248373, encodeId=2eb322483e37a, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：正在投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0e95702647, createdName=ms1000000283885765, createdTime=Thu Jan 16 19:25:47 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230656, encodeId=2e16223065675, content=第一轮大修后迎来小修，小修返回去后editor assigned已经半个月了，请问大家这是什么情况啊。。也不敢发邮件询问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b48346217, createdName=ms3000000263143818, createdTime=Sun Oct 13 21:22:13 CST 2024, time=2024-10-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2160074, encodeId=0ff121600e444, content=Manuscript Under Consideration一般多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=380, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14938341371, createdName=ms6000001571479804, createdTime=Wed Sep 27 18:15:41 CST 2023, time=2023-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=972892, encodeId=24729e289276, content=投稿11天被拒，着急的人慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210611/d83e222ca83744579abc7ae60aec94b4/d3ddb54b1ac74080bbe927391f78ad1a.jpg, createdBy=36415493698, createdName=志志呀, createdTime=Fri Jun 11 16:31:06 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125871, encodeId=ff1d21258e126, content=偏重的研究方向：肝脏;肠道 经验分享：想问问大家审稿2个月了，还没有任何的回复，不会给我拒绝了吧，这么久了。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Fri Apr 14 10:58:54 CST 2023, time=2023-04-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2232131, encodeId=1103223213193, content=请问一下，直接投STTT的研究性Letter难度咋样？比如比起STTT或者其它十分左右杂志的Article，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=sucao, createdTime=Mon Oct 21 14:11:49 CST 2024, time=2024-10-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1059450, encodeId=093c10594501c, content=大家有类似的经历吗？预接收以后过了25天还未正式接收（9月13日预接收，15日返回修改版，之后状态一直是editor assigned）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=402, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhFQWJcqrIHncZhicFVfK89RBPRlh6RHemwCJGbAu6sf2BgPbVkfYbE2KOnIAvbXIk2KFhqbLoIeQ/132, createdBy=45865313245, createdName=cewei, createdTime=Mon Oct 11 13:37:29 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150081, encodeId=b992215008172, content=正在投稿中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d4b5542563, createdName=ms2000002060596419, createdTime=Thu Jul 27 10:52:45 CST 2023, time=2023-07-27, status=1, ipAttribution=广东省)]

2025-01-16 ms1000000283885765 来自北京

审稿速度:2.0 | 投稿命中率:5.0
偏重的研究方向：免疫
经验分享：正在投稿

42 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2265912, encodeId=412c226591236, content=偏重的研究方向：免疫 经验分享：自投综述，无约稿。经历供参考。 ·2025.5.20(周二，上午)发邮件给编辑询问是否接受综述投稿，并提供主要内容。 ·2025.5.20（周二，下午）非常感谢您提交前的询问。提议的主题很有趣也很重要。【然而，我们在类似或更大的主题上也有评审，要么在同行评审中，要么在修订中。因此，这个主题不在我们今年的优先主题列表中。】我们对这个负面的回应感到抱歉。非常感谢您的理解。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffeb5424961, createdName=ms2000001547783895, createdTime=Tue May 20 18:58:16 CST 2025, time=2025-05-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2248369, encodeId=1364224836999, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：还在under Consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0e95702647, createdName=ms1000000283885765, createdTime=Thu Jan 16 19:20:06 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2248373, encodeId=2eb322483e37a, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：正在投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0e95702647, createdName=ms1000000283885765, createdTime=Thu Jan 16 19:25:47 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230656, encodeId=2e16223065675, content=第一轮大修后迎来小修，小修返回去后editor assigned已经半个月了，请问大家这是什么情况啊。。也不敢发邮件询问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b48346217, createdName=ms3000000263143818, createdTime=Sun Oct 13 21:22:13 CST 2024, time=2024-10-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2160074, encodeId=0ff121600e444, content=Manuscript Under Consideration一般多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=380, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14938341371, createdName=ms6000001571479804, createdTime=Wed Sep 27 18:15:41 CST 2023, time=2023-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=972892, encodeId=24729e289276, content=投稿11天被拒，着急的人慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210611/d83e222ca83744579abc7ae60aec94b4/d3ddb54b1ac74080bbe927391f78ad1a.jpg, createdBy=36415493698, createdName=志志呀, createdTime=Fri Jun 11 16:31:06 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125871, encodeId=ff1d21258e126, content=偏重的研究方向：肝脏;肠道 经验分享：想问问大家审稿2个月了，还没有任何的回复，不会给我拒绝了吧，这么久了。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Fri Apr 14 10:58:54 CST 2023, time=2023-04-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2232131, encodeId=1103223213193, content=请问一下，直接投STTT的研究性Letter难度咋样？比如比起STTT或者其它十分左右杂志的Article，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=sucao, createdTime=Mon Oct 21 14:11:49 CST 2024, time=2024-10-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1059450, encodeId=093c10594501c, content=大家有类似的经历吗？预接收以后过了25天还未正式接收（9月13日预接收，15日返回修改版，之后状态一直是editor assigned）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=402, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhFQWJcqrIHncZhicFVfK89RBPRlh6RHemwCJGbAu6sf2BgPbVkfYbE2KOnIAvbXIk2KFhqbLoIeQ/132, createdBy=45865313245, createdName=cewei, createdTime=Mon Oct 11 13:37:29 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150081, encodeId=b992215008172, content=正在投稿中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d4b5542563, createdName=ms2000002060596419, createdTime=Thu Jul 27 10:52:45 CST 2023, time=2023-07-27, status=1, ipAttribution=广东省)]

2024-10-13 ms3000000263143818 来自北京

第一轮大修后迎来小修，小修返回去后editor assigned已经半个月了，请问大家这是什么情况啊。。也不敢发邮件询问

74 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2265912, encodeId=412c226591236, content=偏重的研究方向：免疫 经验分享：自投综述，无约稿。经历供参考。 ·2025.5.20(周二，上午)发邮件给编辑询问是否接受综述投稿，并提供主要内容。 ·2025.5.20（周二，下午）非常感谢您提交前的询问。提议的主题很有趣也很重要。【然而，我们在类似或更大的主题上也有评审，要么在同行评审中，要么在修订中。因此，这个主题不在我们今年的优先主题列表中。】我们对这个负面的回应感到抱歉。非常感谢您的理解。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffeb5424961, createdName=ms2000001547783895, createdTime=Tue May 20 18:58:16 CST 2025, time=2025-05-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2248369, encodeId=1364224836999, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：还在under Consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0e95702647, createdName=ms1000000283885765, createdTime=Thu Jan 16 19:20:06 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2248373, encodeId=2eb322483e37a, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：正在投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0e95702647, createdName=ms1000000283885765, createdTime=Thu Jan 16 19:25:47 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230656, encodeId=2e16223065675, content=第一轮大修后迎来小修，小修返回去后editor assigned已经半个月了，请问大家这是什么情况啊。。也不敢发邮件询问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b48346217, createdName=ms3000000263143818, createdTime=Sun Oct 13 21:22:13 CST 2024, time=2024-10-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2160074, encodeId=0ff121600e444, content=Manuscript Under Consideration一般多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=380, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14938341371, createdName=ms6000001571479804, createdTime=Wed Sep 27 18:15:41 CST 2023, time=2023-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=972892, encodeId=24729e289276, content=投稿11天被拒，着急的人慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210611/d83e222ca83744579abc7ae60aec94b4/d3ddb54b1ac74080bbe927391f78ad1a.jpg, createdBy=36415493698, createdName=志志呀, createdTime=Fri Jun 11 16:31:06 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125871, encodeId=ff1d21258e126, content=偏重的研究方向：肝脏;肠道 经验分享：想问问大家审稿2个月了，还没有任何的回复，不会给我拒绝了吧，这么久了。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Fri Apr 14 10:58:54 CST 2023, time=2023-04-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2232131, encodeId=1103223213193, content=请问一下，直接投STTT的研究性Letter难度咋样？比如比起STTT或者其它十分左右杂志的Article，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=sucao, createdTime=Mon Oct 21 14:11:49 CST 2024, time=2024-10-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1059450, encodeId=093c10594501c, content=大家有类似的经历吗？预接收以后过了25天还未正式接收（9月13日预接收，15日返回修改版，之后状态一直是editor assigned）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=402, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhFQWJcqrIHncZhicFVfK89RBPRlh6RHemwCJGbAu6sf2BgPbVkfYbE2KOnIAvbXIk2KFhqbLoIeQ/132, createdBy=45865313245, createdName=cewei, createdTime=Mon Oct 11 13:37:29 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150081, encodeId=b992215008172, content=正在投稿中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d4b5542563, createdName=ms2000002060596419, createdTime=Thu Jul 27 10:52:45 CST 2023, time=2023-07-27, status=1, ipAttribution=广东省)]

2023-09-27 ms6000001571479804 来自湖北省

Manuscript Under Consideration一般多久呀

380 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2265912, encodeId=412c226591236, content=偏重的研究方向：免疫 经验分享：自投综述，无约稿。经历供参考。 ·2025.5.20(周二，上午)发邮件给编辑询问是否接受综述投稿，并提供主要内容。 ·2025.5.20（周二，下午）非常感谢您提交前的询问。提议的主题很有趣也很重要。【然而，我们在类似或更大的主题上也有评审，要么在同行评审中，要么在修订中。因此，这个主题不在我们今年的优先主题列表中。】我们对这个负面的回应感到抱歉。非常感谢您的理解。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffeb5424961, createdName=ms2000001547783895, createdTime=Tue May 20 18:58:16 CST 2025, time=2025-05-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2248369, encodeId=1364224836999, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：还在under Consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0e95702647, createdName=ms1000000283885765, createdTime=Thu Jan 16 19:20:06 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2248373, encodeId=2eb322483e37a, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：正在投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0e95702647, createdName=ms1000000283885765, createdTime=Thu Jan 16 19:25:47 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230656, encodeId=2e16223065675, content=第一轮大修后迎来小修，小修返回去后editor assigned已经半个月了，请问大家这是什么情况啊。。也不敢发邮件询问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b48346217, createdName=ms3000000263143818, createdTime=Sun Oct 13 21:22:13 CST 2024, time=2024-10-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2160074, encodeId=0ff121600e444, content=Manuscript Under Consideration一般多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=380, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14938341371, createdName=ms6000001571479804, createdTime=Wed Sep 27 18:15:41 CST 2023, time=2023-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=972892, encodeId=24729e289276, content=投稿11天被拒，着急的人慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210611/d83e222ca83744579abc7ae60aec94b4/d3ddb54b1ac74080bbe927391f78ad1a.jpg, createdBy=36415493698, createdName=志志呀, createdTime=Fri Jun 11 16:31:06 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125871, encodeId=ff1d21258e126, content=偏重的研究方向：肝脏;肠道 经验分享：想问问大家审稿2个月了，还没有任何的回复，不会给我拒绝了吧，这么久了。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Fri Apr 14 10:58:54 CST 2023, time=2023-04-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2232131, encodeId=1103223213193, content=请问一下，直接投STTT的研究性Letter难度咋样？比如比起STTT或者其它十分左右杂志的Article，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=sucao, createdTime=Mon Oct 21 14:11:49 CST 2024, time=2024-10-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1059450, encodeId=093c10594501c, content=大家有类似的经历吗？预接收以后过了25天还未正式接收（9月13日预接收，15日返回修改版，之后状态一直是editor assigned）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=402, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhFQWJcqrIHncZhicFVfK89RBPRlh6RHemwCJGbAu6sf2BgPbVkfYbE2KOnIAvbXIk2KFhqbLoIeQ/132, createdBy=45865313245, createdName=cewei, createdTime=Mon Oct 11 13:37:29 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150081, encodeId=b992215008172, content=正在投稿中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d4b5542563, createdName=ms2000002060596419, createdTime=Thu Jul 27 10:52:45 CST 2023, time=2023-07-27, status=1, ipAttribution=广东省)]

2021-06-11 志志呀

投稿11天被拒，着急的人慎投

154 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2265912, encodeId=412c226591236, content=偏重的研究方向：免疫 经验分享：自投综述，无约稿。经历供参考。 ·2025.5.20(周二，上午)发邮件给编辑询问是否接受综述投稿，并提供主要内容。 ·2025.5.20（周二，下午）非常感谢您提交前的询问。提议的主题很有趣也很重要。【然而，我们在类似或更大的主题上也有评审，要么在同行评审中，要么在修订中。因此，这个主题不在我们今年的优先主题列表中。】我们对这个负面的回应感到抱歉。非常感谢您的理解。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffeb5424961, createdName=ms2000001547783895, createdTime=Tue May 20 18:58:16 CST 2025, time=2025-05-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2248369, encodeId=1364224836999, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：还在under Consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0e95702647, createdName=ms1000000283885765, createdTime=Thu Jan 16 19:20:06 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2248373, encodeId=2eb322483e37a, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：正在投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0e95702647, createdName=ms1000000283885765, createdTime=Thu Jan 16 19:25:47 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230656, encodeId=2e16223065675, content=第一轮大修后迎来小修，小修返回去后editor assigned已经半个月了，请问大家这是什么情况啊。。也不敢发邮件询问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b48346217, createdName=ms3000000263143818, createdTime=Sun Oct 13 21:22:13 CST 2024, time=2024-10-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2160074, encodeId=0ff121600e444, content=Manuscript Under Consideration一般多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=380, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14938341371, createdName=ms6000001571479804, createdTime=Wed Sep 27 18:15:41 CST 2023, time=2023-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=972892, encodeId=24729e289276, content=投稿11天被拒，着急的人慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210611/d83e222ca83744579abc7ae60aec94b4/d3ddb54b1ac74080bbe927391f78ad1a.jpg, createdBy=36415493698, createdName=志志呀, createdTime=Fri Jun 11 16:31:06 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125871, encodeId=ff1d21258e126, content=偏重的研究方向：肝脏;肠道 经验分享：想问问大家审稿2个月了，还没有任何的回复，不会给我拒绝了吧，这么久了。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Fri Apr 14 10:58:54 CST 2023, time=2023-04-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2232131, encodeId=1103223213193, content=请问一下，直接投STTT的研究性Letter难度咋样？比如比起STTT或者其它十分左右杂志的Article，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=sucao, createdTime=Mon Oct 21 14:11:49 CST 2024, time=2024-10-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1059450, encodeId=093c10594501c, content=大家有类似的经历吗？预接收以后过了25天还未正式接收（9月13日预接收，15日返回修改版，之后状态一直是editor assigned）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=402, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhFQWJcqrIHncZhicFVfK89RBPRlh6RHemwCJGbAu6sf2BgPbVkfYbE2KOnIAvbXIk2KFhqbLoIeQ/132, createdBy=45865313245, createdName=cewei, createdTime=Mon Oct 11 13:37:29 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150081, encodeId=b992215008172, content=正在投稿中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d4b5542563, createdName=ms2000002060596419, createdTime=Thu Jul 27 10:52:45 CST 2023, time=2023-07-27, status=1, ipAttribution=广东省)]

2023-04-14 ms9000000615443695 来自天津

偏重的研究方向：肝脏;肠道
经验分享：想问问大家审稿2个月了，还没有任何的回复，不会给我拒绝了吧，这么久了。。。。。。。

340 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2265912, encodeId=412c226591236, content=偏重的研究方向：免疫 经验分享：自投综述，无约稿。经历供参考。 ·2025.5.20(周二，上午)发邮件给编辑询问是否接受综述投稿，并提供主要内容。 ·2025.5.20（周二，下午）非常感谢您提交前的询问。提议的主题很有趣也很重要。【然而，我们在类似或更大的主题上也有评审，要么在同行评审中，要么在修订中。因此，这个主题不在我们今年的优先主题列表中。】我们对这个负面的回应感到抱歉。非常感谢您的理解。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffeb5424961, createdName=ms2000001547783895, createdTime=Tue May 20 18:58:16 CST 2025, time=2025-05-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2248369, encodeId=1364224836999, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：还在under Consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0e95702647, createdName=ms1000000283885765, createdTime=Thu Jan 16 19:20:06 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2248373, encodeId=2eb322483e37a, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：正在投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0e95702647, createdName=ms1000000283885765, createdTime=Thu Jan 16 19:25:47 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230656, encodeId=2e16223065675, content=第一轮大修后迎来小修，小修返回去后editor assigned已经半个月了，请问大家这是什么情况啊。。也不敢发邮件询问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b48346217, createdName=ms3000000263143818, createdTime=Sun Oct 13 21:22:13 CST 2024, time=2024-10-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2160074, encodeId=0ff121600e444, content=Manuscript Under Consideration一般多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=380, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14938341371, createdName=ms6000001571479804, createdTime=Wed Sep 27 18:15:41 CST 2023, time=2023-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=972892, encodeId=24729e289276, content=投稿11天被拒，着急的人慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210611/d83e222ca83744579abc7ae60aec94b4/d3ddb54b1ac74080bbe927391f78ad1a.jpg, createdBy=36415493698, createdName=志志呀, createdTime=Fri Jun 11 16:31:06 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125871, encodeId=ff1d21258e126, content=偏重的研究方向：肝脏;肠道 经验分享：想问问大家审稿2个月了，还没有任何的回复，不会给我拒绝了吧，这么久了。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Fri Apr 14 10:58:54 CST 2023, time=2023-04-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2232131, encodeId=1103223213193, content=请问一下，直接投STTT的研究性Letter难度咋样？比如比起STTT或者其它十分左右杂志的Article，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=sucao, createdTime=Mon Oct 21 14:11:49 CST 2024, time=2024-10-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1059450, encodeId=093c10594501c, content=大家有类似的经历吗？预接收以后过了25天还未正式接收（9月13日预接收，15日返回修改版，之后状态一直是editor assigned）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=402, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhFQWJcqrIHncZhicFVfK89RBPRlh6RHemwCJGbAu6sf2BgPbVkfYbE2KOnIAvbXIk2KFhqbLoIeQ/132, createdBy=45865313245, createdName=cewei, createdTime=Mon Oct 11 13:37:29 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150081, encodeId=b992215008172, content=正在投稿中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d4b5542563, createdName=ms2000002060596419, createdTime=Thu Jul 27 10:52:45 CST 2023, time=2023-07-27, status=1, ipAttribution=广东省)]

2024-10-21 sucao 来自湖南省

请问一下，直接投STTT的研究性Letter难度咋样？比如比起STTT或者其它十分左右杂志的Article，谢谢。

0 0

[GetPortalCommentsPageByObjectIdResponse(id=2265912, encodeId=412c226591236, content=偏重的研究方向：免疫 经验分享：自投综述，无约稿。经历供参考。 ·2025.5.20(周二，上午)发邮件给编辑询问是否接受综述投稿，并提供主要内容。 ·2025.5.20（周二，下午）非常感谢您提交前的询问。提议的主题很有趣也很重要。【然而，我们在类似或更大的主题上也有评审，要么在同行评审中，要么在修订中。因此，这个主题不在我们今年的优先主题列表中。】我们对这个负面的回应感到抱歉。非常感谢您的理解。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffeb5424961, createdName=ms2000001547783895, createdTime=Tue May 20 18:58:16 CST 2025, time=2025-05-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2248369, encodeId=1364224836999, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：还在under Consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0e95702647, createdName=ms1000000283885765, createdTime=Thu Jan 16 19:20:06 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2248373, encodeId=2eb322483e37a, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：正在投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0e95702647, createdName=ms1000000283885765, createdTime=Thu Jan 16 19:25:47 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230656, encodeId=2e16223065675, content=第一轮大修后迎来小修，小修返回去后editor assigned已经半个月了，请问大家这是什么情况啊。。也不敢发邮件询问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b48346217, createdName=ms3000000263143818, createdTime=Sun Oct 13 21:22:13 CST 2024, time=2024-10-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2160074, encodeId=0ff121600e444, content=Manuscript Under Consideration一般多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=380, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14938341371, createdName=ms6000001571479804, createdTime=Wed Sep 27 18:15:41 CST 2023, time=2023-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=972892, encodeId=24729e289276, content=投稿11天被拒，着急的人慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210611/d83e222ca83744579abc7ae60aec94b4/d3ddb54b1ac74080bbe927391f78ad1a.jpg, createdBy=36415493698, createdName=志志呀, createdTime=Fri Jun 11 16:31:06 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125871, encodeId=ff1d21258e126, content=偏重的研究方向：肝脏;肠道 经验分享：想问问大家审稿2个月了，还没有任何的回复，不会给我拒绝了吧，这么久了。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Fri Apr 14 10:58:54 CST 2023, time=2023-04-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2232131, encodeId=1103223213193, content=请问一下，直接投STTT的研究性Letter难度咋样？比如比起STTT或者其它十分左右杂志的Article，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=sucao, createdTime=Mon Oct 21 14:11:49 CST 2024, time=2024-10-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1059450, encodeId=093c10594501c, content=大家有类似的经历吗？预接收以后过了25天还未正式接收（9月13日预接收，15日返回修改版，之后状态一直是editor assigned）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=402, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhFQWJcqrIHncZhicFVfK89RBPRlh6RHemwCJGbAu6sf2BgPbVkfYbE2KOnIAvbXIk2KFhqbLoIeQ/132, createdBy=45865313245, createdName=cewei, createdTime=Mon Oct 11 13:37:29 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150081, encodeId=b992215008172, content=正在投稿中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d4b5542563, createdName=ms2000002060596419, createdTime=Thu Jul 27 10:52:45 CST 2023, time=2023-07-27, status=1, ipAttribution=广东省)]

2021-10-11 cewei

大家有类似的经历吗？预接收以后过了25天还未正式接收（9月13日预接收，15日返回修改版，之后状态一直是editor assigned）。

402 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2265912, encodeId=412c226591236, content=偏重的研究方向：免疫 经验分享：自投综述，无约稿。经历供参考。 ·2025.5.20(周二，上午)发邮件给编辑询问是否接受综述投稿，并提供主要内容。 ·2025.5.20（周二，下午）非常感谢您提交前的询问。提议的主题很有趣也很重要。【然而，我们在类似或更大的主题上也有评审，要么在同行评审中，要么在修订中。因此，这个主题不在我们今年的优先主题列表中。】我们对这个负面的回应感到抱歉。非常感谢您的理解。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffeb5424961, createdName=ms2000001547783895, createdTime=Tue May 20 18:58:16 CST 2025, time=2025-05-20, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2248369, encodeId=1364224836999, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：还在under Consideration, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0e95702647, createdName=ms1000000283885765, createdTime=Thu Jan 16 19:20:06 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2248373, encodeId=2eb322483e37a, content=审稿速度:2.0 | 投稿命中率:5.0 偏重的研究方向：免疫 经验分享：正在投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0e95702647, createdName=ms1000000283885765, createdTime=Thu Jan 16 19:25:47 CST 2025, time=2025-01-16, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2230656, encodeId=2e16223065675, content=第一轮大修后迎来小修，小修返回去后editor assigned已经半个月了，请问大家这是什么情况啊。。也不敢发邮件询问, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b48346217, createdName=ms3000000263143818, createdTime=Sun Oct 13 21:22:13 CST 2024, time=2024-10-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2160074, encodeId=0ff121600e444, content=Manuscript Under Consideration一般多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=380, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=14938341371, createdName=ms6000001571479804, createdTime=Wed Sep 27 18:15:41 CST 2023, time=2023-09-27, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=972892, encodeId=24729e289276, content=投稿11天被拒，着急的人慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210611/d83e222ca83744579abc7ae60aec94b4/d3ddb54b1ac74080bbe927391f78ad1a.jpg, createdBy=36415493698, createdName=志志呀, createdTime=Fri Jun 11 16:31:06 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2125871, encodeId=ff1d21258e126, content=偏重的研究方向：肝脏;肠道 经验分享：想问问大家审稿2个月了，还没有任何的回复，不会给我拒绝了吧，这么久了。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=340, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a916553150, createdName=ms9000000615443695, createdTime=Fri Apr 14 10:58:54 CST 2023, time=2023-04-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2232131, encodeId=1103223213193, content=请问一下，直接投STTT的研究性Letter难度咋样？比如比起STTT或者其它十分左右杂志的Article，谢谢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a8b65561438, createdName=sucao, createdTime=Mon Oct 21 14:11:49 CST 2024, time=2024-10-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1059450, encodeId=093c10594501c, content=大家有类似的经历吗？预接收以后过了25天还未正式接收（9月13日预接收，15日返回修改版，之后状态一直是editor assigned）。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=402, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKhFQWJcqrIHncZhicFVfK89RBPRlh6RHemwCJGbAu6sf2BgPbVkfYbE2KOnIAvbXIk2KFhqbLoIeQ/132, createdBy=45865313245, createdName=cewei, createdTime=Mon Oct 11 13:37:29 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2150081, encodeId=b992215008172, content=正在投稿中 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5d4b5542563, createdName=ms2000002060596419, createdTime=Thu Jul 27 10:52:45 CST 2023, time=2023-07-27, status=1, ipAttribution=广东省)]

2023-07-27 ms2000002060596419 来自广东省

正在投稿中

374 5

展开5条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务